Rabbit Polyclonal AGXT Antibody

The AGXT antibody targets alanine-glyoxylate aminotransferase (AGXT), a liver-specific peroxisomal enzyme encoded by the AGXT gene. This enzyme plays a critical role in glyoxylate metabolism, catalyzing the conversion of alanine and glyoxylate to pyruvate and glycine. Dysfunction of AGXT due to genetic mutations leads to primary hyperoxaluria type 1 (PH1), a rare autosomal recessive disorder characterized by excessive oxalate production, resulting in kidney stones, nephrocalcinosis, and systemic oxalosis. AGXT antibodies are widely used in research to study the enzyme's expression, localization, and functional abnormalities in PH1. They enable detection of AGXT protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in the characterization of disease mechanisms and mutation-specific effects. Additionally, these antibodies are employed in preclinical studies to evaluate therapeutic interventions, such as enzyme replacement therapies or gene-editing approaches aimed at restoring AGXT activity. Commercially available AGXT antibodies are typically raised against specific epitopes of the human AGXT protein, ensuring specificity for diagnostic and experimental applications. Their development has significantly advanced understanding of glyoxylate metabolism disorders and continues to support translational research toward targeted treatments for PH1.